CorFlow Therapeutics AG, a clinical-stage company pioneering combined diagnosis and therapy systems for coronary microvascular obstructions (MVO), presented interim positive results from its MOCA I trial at the EuroPCR conference in Paris, France.
The trail showed that its first-of-its-kind real-time catheter-based system is not only able to safety and effectively detect MVO immediately after primary percutaneous coronary intervention (PPCI), but also quickly deliver timely therapeutic intracoronary agents to treat the condition.
The 30 patient clinical trial, which focused on those with ST elevation myocardial infarction (STEMI), the most severe type of heart attack, demonstrated that CorFlow’s approach holds great promise in improving outcomes from coronary microvascular obstructions.
CorFlow is revolutionizing cardiovascular care with the development of their next-generation fully-integrated CoFI system. This cutting-edge technology will soon undergo a pivotal trial before making its much-anticipated commercial launch. While this state-of-the-art device cannot yet be distributed, its revolutionary potential is certainly something to be excited about!
The new PCoFI pressure parameter, implemented by the CoFI system, was evaluated for its ability to detect MVO. Results showed PCoFI was highly accurate, providing a sensitivity of 95%, specificity of 91%, and an AUC of 0.94 when compared with cardiac MRI as the reference standard.
The CoFI device and procedure were also found to be safe, with no device-related deaths, flow-limiting dissections or thrombotic events at 30 days according to an independent Clinical Events Committee. Thanks to this development, PCoFI is now a groundbreaking achievement in the detection of MVO.
Professor Dr. Marco Valgimigli, Deputy Chief of Cardiology at the Cardiocentro Ticino Institute in Lugano, Switzerland, has unveiled a groundbreaking study, the MOCA I study, providing a potential solution to accurately and early detect high-risk patients and provide targeted treatment. His findings suggest that MVO can now be detected confidently and directly at the end of primary PCI. This revolutionary discovery could be the first step to providing a lifeline for those affected and it is an advance that warrants further exploration.
The unprecedented advancements in the field of interventional cardiology in the last couple of decades have been life-saving for many, often mitigating the consequences of serious cardiac episodes such as a heart attack. However, many patients still fare poorly in the long run, despite the current standard of care treatments.
It has been discovered that at least 50% of those having suffered a heart attack possess MVO, which is the single strongest predictive factor for detrimental outcomes, including heart failure and death.
With cardiovascular diseases accounting for the most number of fatalities all over the world, most of which resulted from strokes and heart attacks, targeting the blockages in the coronary microcirculation could potentially prove to be a game-changer, reducing this worrying global burden.
The data from the MOCA I study with the CorFlow system has been incredibly encouraging for cardiologists, who are increasingly recognizing the importance of microvascular obstruction (MVO) and microvascular disease. This rapidly developing field is an exciting opportunity to improve outcomes for patients, and CorFlow technologies are leading the way with their ability to diagnose MVO and other microvascular conditions in the cath lab.
With this technology, we are now able to offer additional therapy options for better patient care. Dr. Azeem Latib of Montefiore Medical Center in New York City notes that treating large vessels is no longer enough, and that we can only anticipate greater strides forward in managing microvascular disease.
The CoFI System is poised to revolutionize the field of interventional cardiology by providing healthcare professionals with access to real-time catheter-based MVO detection. This advanced technology is designed to inform immediate treatment decisions and optimize patient outcomes, particularly for those suffering from a STEMI heart attack.
According to CorFlow CEO Paul Mead, the CoFI System is a breakthrough technology with the potential to dramatically improve the lives of those affected by MVO. The results of the MOCA I trial show that advanced treatments such as this have the potential to make a real difference.
About the CorFlow CoFI System
The groundbreaking Controlled Flow Infusion (CoFI) System ushers in a new era of diagnostic assessments for the coronary microcirculation in the cath lab. This technologically-advanced system uses proprietary software algorithms to detect potentially life-threatening conditions like microvascular obstruction (MVO) and other conditions related to microvascular function.
Composed of a next generation console, an advanced proprietary catheter with a pressure sensor wire, and single use infusion cassette, the CoFI System promises to revolutionize diagnostic and therapeutic interventions in coronary and broader vascular use cases with the support of a broad patent family.
CorFlow Therapeutics AG, a groundbreaking venture-backed company based in Switzerland, is pushing forward the boundaries of medical technology and cardiology with the mission to improve and save lives.
Founded by two renowned interventional cardiologists – Dr. Rob Schwartz and Dr. Martin Rothman – who discovered unmet demands after decades of work, the company is now raising its Series B funding to prioritize its ambitions. The firm is already conducting the European “MOCA I” trial with its CoFI System, and is optimistically preparing for US clinical trials and commercialization of its products.